1. Scrip
  2. >>Business

IPO Update: Novan, AC Immune End Summer Slowdown As Market Improves

 
• By Mandy Jackson

Novan and AC Immune ended September with the first biopharma IPOs in 40 days as the performance of newly public companies’ stocks head into an upswing.

stock

Novan Inc. on Sept. 20 was the first biopharmaceutical company to launch an initial public offering in the US since Protagonist Therapeutics Inc. went public on Aug. 10 and AC Immune SA followed with an IPO of its own on Sept. 22, ending a summer slowdown with two successful offerings.

Dermatology-focused Novan and the Swiss neurodegenerative disease specialist AC Immune both priced their offerings at $11 per share, which was...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

AstraZeneca Taps Into China’s R&D Engine With CSPC Alliance

 
• By Andrew McConaghie

After in-licensing a cardiovascular candidate last year, AstraZeneca has signed a strategic drug discovery alliance, which could generate billions of dollars in payments to the Chinese firm.

Executives On The Move: New CMOs At Instil Bio, Nkarta & Catalyst Pharma

Recent moves in the industry include changes at the top at iOnctura and Orca Bio, plus Sutro Biopharma, Tenpoint Therapeutics and Helix BioPharma get new CFOs.

In Brief: Starton Moves Low-Dose Lenalidomide To Phase IIa For Multiple Myeloma

 
• By Sushmita Panda

Study to add to safety and tolerability data for infused formulation and may help identify optimal dose for future pivotal trial.